Correo Electrónico
DNINFOA - SIA
Bibliotecas
Convocatorias
Identidad U.N.
Publicado
A computational predicting of possible inhibitors of the main SARS-CoV-2 protease found in Algerian herbal medicines
Una predicción computacional de los posibles inhibidores de la principal proteasa del SARS-CoV-2 que se encuentra en las hierbas medicinales argelinas
Um prevendo computacional de possível inibidores da principal protease SARS-CoV-2 encontrada em fitoterápicos argelinos
DOI:
https://doi.org/10.15446/rev.colomb.quim.v51n3.106949Palabras clave:
SARS-CoV-2, Warfarin, ADMET, Molecular docking, Molecular dynamics (en)SARS-CoV-2, warfarina, ADMET, docking molecular, Dinámica molecular (es)
SARS-CoV-2, Varfarina, ADMET, Docking molecular, Dinâmica molecular (pt)
Descargas
COVID-19 is a zoonotic viral disease caused by the SARS-CoV-2 virus. Its abrupt outbreak has caused a tremendous challenge to public health systems due to the rapid spread of the virus. In this sense, a great deal of work has been focused on finding substances from herbal plants to be used against this virus. In order to investigate the molecular interactions between natural metabolites from Algerian herbal plants and the SARS-CoV-2 protease Mpro, computational docking and molecular dynamics were used, also the drug likeness degree and in silico ADMET prediction were carried out in this study. warfarin and catalponol preferentially binds to a pocket of the SARS-Cov-2 Mpro active site that is made up of residues His 41 to Glu 166 and Leu 27 to His 163 with a relatively low binding energy of -7.1 and -6.6 kcal/mol respectively. Dynamic molecular assay further established that only warfarin managed to stay in the active site. The results suggest that warfarin may be an interesting candidate for development as a medical treatment of COVID-19 and more research is proposed, without disregarding its toxicity which deserves to be well studied.
El COVID-19 es una enfermedad zoonótica causada por el virus SARS-CoV-2. Su abrupto brote en años recientes ha supuesto un tremendo desafío para los sistemas de salud pública, como resultado de la rápida propagación del virus. En tal sentido, muchos trabajos se han centrado en encontrar sustancias de origen vegetal, para ser utilizadas contra este virus. Se realizaron estudios de acoplamiento computacional y dinámica molecular para investigar las interacciones moleculares entre los metabolitos secundarios de las plantas herbales argelinas con la Proteasa Mpro del SARS-CoV-2, también se realizaron estudios de semejanza con drogas mediante ADMET computacional. La warfarina y el catalponol se unen preferentemente al sitio activo SARS-Cov-2 Mpro que se compone de residuos His 41 a Glu 166 y Leu 27 a His 163 con una energía de enlace relativamente baja, -7,1 y -6,6 kcal/mol respectivamente. Los ensayos de dinámica molecular establecieron además que sólo la warfarina logró permanecer en el sitio activo. Estos resultados sugieren que la warfarina puede ser un candidato interesante para el desarrollo como tratamiento médico de COVID-19 e instan a realizar más investigaciones, sin dejar dejar de lado estudios de toxicidad respectivos.
A COVID-19 é uma doença zoonótica causada pelo vírus SARS-CoV-2, cujo surto abrupto nos últimos anos representou um tremendo desafio para os sistemas de saúde pública devido à rápida disseminação do vírus. Nesse sentido, muitos trabalhos têm se concentrado em encontrar substâncias de origem vegetal, para serem utilizadas contra esse vírus. Estudos de ancoragem computacional e dinâmica molecular foram conduzidos para investigar as interações moleculares entre metabólitos secundários de ervas argelinas com o SARS-CoV-2 Protease Mpro, estudos de similaridade de drogas também foram conduzidos usando ADMET in silico. A varfarina e o catalponol ligam-se preferencialmente ao sítio ativo SARS-Cov-2 Mpro que é composto pelos resíduos His 41 a Glu 166 e Leu 27 a His 163 com uma energia de ligação relativamente baixa, -7,1 e -6,6 kcal/mol, respectivamente. Ensaios de dinâmica molecular estabeleceram ainda que apenas a varfarina conseguiu permanecer no sítio ativo. Esses resultados sugerem que a varfarina pode ser um candidato interessante para desenvolvimento como tratamento médico para COVID-19 e exigem mais pesquisas, incluindo os respectivos estudos de toxicidade.
Referencias
A.K. Singh, A. Singh, A. Shaikh, R. Singh, and A. Misra, “Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries”, Diabetes Metab Syndr Clin Res Rev., vol. 14, pp. 241-246, 2020, DOI: https://doi.org/10.1016/j.dsx.2020.03.011.
F. Wu, S Zhao, B Yu, Y.M. Chen, W. Wang, Z.G. Song, et al., “A new coronavirus associated with human respiratory disease in China”, Nature, vol. 579, pp. 265-269, 2020, DOI: https://doi.org/10.1038/s41586-020-2008-3.
D.S. Hui and A. Zumla, “Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features”, Infect Dis Clin, vol. 33, pp. 869-889, 2019, DOI: https://doi.org/10.1016/j.idc.2019.07.001.
C. Wu, Y. Liu, Y. Yang, P. Zhang, W Zhong, Y. Wang, et al., “Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods”, Acta Pharm Sin B, vol. 10 n°5, pp. 766-788, 2020, DOI: https://doi.org/10.1016/j.apsb.2020.02.008.
N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, et al., “A novel coronavirus from patients with pneumonia in China 2019”, New Engl J Med, vol. 382, n° 8, 727-733, 2020, DOI: https://doi.org/10.1056/nejmoa2001017.
Committee GO of NH, Office of State Administration of Traditional Chinese Medicine. “Notice on the issuance of a programme for the diagnosis and treatment of novel coronavirus (2019-nCoV) infected pneumonia (Trial Version 4)”. 2020.
Z. Song, Y. Xu, L. Bao, L. Zhang, P. Yu, Y. Qu, et al., “From SARS to MERS, thrusting coronaviruses into the spotlight”, Viruses, vol. 11, n° 1, p. 59, 2019, DOI: https://doi.org/10.3390/v11010059.
J.B. Radke, J.M. Kingery, J. Maakestad, and M.D. Krasowski, “Diagnostic pitfalls and laboratory test interference after hydroxychloroquine intoxication: A case report”, Toxicol Rep, vol. 6, pp. 1040-1046, 2019, DOI: https://doi.org/10.1016/j.toxrep.2019.10.006.
J.A. Al-Tawfiq, A.H. Al-Homoud, and Z.A. Memish, “Remdesivir as a possible therapeutic option for the COVID-19”, Travel Med Infect Dis, vol. 34, 101615, 2020, DOI: https://doi.org/10.1016/j.tmaid.2020.101615.
Z. Sahraei, M. Shabani, S. Shokouhi, and A. Saffaei, “Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine” Int J Antimicrob Agents, vol. 55, n° 4, 105945, 2020, DOI: https://doi.org/10.1016/j.ijantimicag.2020.105945.
A.C. Tsang, S. Ahmadi, J. Hamilton, J. Gao, G. Virgili, S.G. Coupland, et al., “The Diagnostic Utility of Multifocal Electroretinography in Detecting Chloroquine and Hydroxychloroquine Retinal Toxicity”, Am J Ophthalmol, vol. 206, pp. 132-139, 2019, DOI: https://doi.org/10.1016/j.ajo.2019.04.025.
WHO “discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19”, https://www.who.int/news/item/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19 (Last access: October 25, 2020).
M. Tahir ul Qamar, S.M. Alqahtani, M.A. Alamri, and L.L. Chen, “Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants”, J Pharm Anal, vol. 10, pp. 313-319, 2020, DOI: https://doi.org/10.1016/j.jpha.2020.03.009.
S.-S Ou-Yang, J.-Y Lu, X.-Q Kong, Z-J Liang, C. Luo, and H. Jiang, “Computational drug discovery”, Acta Pharmacologica Sinica, pp. 1131-1140, 2012, DOI: https://doi.org/10.1038/aps.2012.109.
M. Hassanzadeganroudsari, A.H. Ahmadi, N. Rashidi, M.K.Hossain, A. Habib, and V. Apostolopoulos, “Computational Chemistry to Repurposing Drugs for the Control of COVID-19”, Biologics, pp. 111-128, 2021, DOI: https://www.mdpi.com/2673-8449/1/2/7#. DOI: https://doi.org/10.3390/biologics1020007
G. F. Leonardo, N. d S. Ricardo, O. Glaucius, and D.A. Adriano, “Molecular Docking and Structure-Based Drug Design Strategies”, Molecules, pp. 13384-13421, 2015, DOI: https://doi.org/10.3390/molecules200713384.
J. Vamathevan, D. Clark, P. Czodrowski, I. Dunham, E. Ferran, G. Lee, B. Li, A. Madabhushi, P. Shah, M. Spitzer, and S. Zhao, “Applications of machine learning in drug discovery and development”, Nat Rev Drug Discov, vol. 18, pp. 463-477, 2019, DOI: https://doi.org/10.1038/s41573-019-0024-5.
E.N. Muratov, R. Amaro, C.H. Andrade, N. Brown, S. Ekins, D. Fourches, et al., “A critical overview of computational approaches employed for COVID-19 drug discovery”, Chem Soc Rev, vol.50(16), pp. 9121-9151, 2021, DOI: https://doi.org/10.1039/D0CS01065K.
B.M. Sahoo, S.K. Bhattamisra, S. Das, A. Tiwari, V. Tiwari, M. Kumar, and S. Singh, “Computational Approach to Combat COVID-19 Infection: Emerging Tools for Accelerating Drug Research”, Curr Drug Discov Technol, vol. 19(3), e170122200314, 2022, DOI: https://doi.org/10.2174/1570163819666220117161308.
C.C. Chang, H.J. Hsu, T.Y. Wu, and J.W. Liou, “Computer-aided discovery, design, and investigation of COVID-19 therapeutics”, Tzu Chi Med J, vol. 34(3), pp. 276-86, 2022, DOI: https://doi.org/10.4103%2Ftcmj.tcmj_318_21.
I. Aanouz, A. Belhassan, K. El Khatabi, T. Lakhlifi, M. El Idrissi, and M. Bouachrine, “Moroccan Medicinal plants as inhibitors of COVID-19: Computational investigations”, J Biomol Struct Dyn, pp. 1-12, 2020, DOI: https://doi.org/10.1080/07391102.2020.1758790.
M. Hakmi, E.M. Bouricha, I. Kandoussi, J. El. Harti, and A. Ibrahimi, “Repurposing of known anti-virals as potential inhibitors for SARS-CoV-2 main protease using molecular docking analysis”, Bioinformation, vol. 16, pp. 301-306, 2020, DOI: https://doi.org/10.6026%2F97320630016301.
Y.H. Zhao, M.H. Abraham, J. Le, A. Hersey, C.N. Luscombe, G. Beck, et al., “Rate-Limited Steps of Human Oral Absorption and QSAR Studies”, Pharm Res, vol. 19, pp. 1446-1457, 2002, DOI: https://doi.org/10.1023/a:1020444330011.
R. Madan, K. Pandit, H. Kumar, N. Kumari, and S. Singh, “Principles and aspects of molecular docking: A bird’s eye view”, Hans Shodh Sudha, vol. 1(1), pp. 110-121, 2020.
J. Fan, A. Fu, and L. Zhang, “Progress in molecular docking”, Quant Biol, vol. 7(2), pp. 83‒89, 2019, DOI: https://doi.org/10.1007/s40484-019-0172-y.
B. Yabrir, M. Touati, B. Adli, E. Bezini, M. Ghafoul, S. Khalifa, and B. Guit, “Therapeutic use of spontaneous medicinal flora from an extreme environment (dune cordon) in Djelfa region, Algeria”, J Pharm Pharmacogn Res, vol. 6(5), pp. 358-373, 2018.
Z. Chen, and T. Nakamura, “Statistical evidence for the usefulness of Chinese medicine in the treatment of SARS”, Phytother Res Int J Devoted Pharmacol Toxicol Eval Nat Prod Deriv, vol. 18, pp. 592-594, 2004, DOI: https://doi.org/10.1002/ptr.1485.
H.E. Pence and A. Williams, “ChemSpider: An Online Chemical Information Resource”. J Chem Educ, vol. 87, pp. 1123-1134, 2010, DOI: https://doi.org/10.1021/ed100697w.
D.S. Wishart, Y.D. Feunang, A.C. Guo, E.J. Lo, A. Marcu, J.R. Grant, et al., “DrugBank 5.0: a major update to the DrugBank database for 2018”, Nucleic Acids Res, vol. 46, pp. 1074-1082, 2018. DOI: https://doi.org/10.1093/nar/gkx1037
Protein Data Bank PDB. http://www.rcsb.org n.d.
C.A. Hunter, K.R. Lawson, J. Perkins, and C.J. Urch, “Aromatic interactions”, J Chem Soc Perkin Trans, vol. 0, pp. 651-669, 2001, DOI: https://doi.org/10.1039/B008495F.
O. Trott, and A.J. Olson, “AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading”, J Comput Chem, vol. 31, pp. 55-461, 2010, DOI: https://doi.org/10.1002%2Fjcc.21334.
S. Noreen, S.H. Sumrra, Z.H. Chohan, G. Mustafa, and M. Imran, “Synthesis, characterization, molecular docking and network pharmacology of bioactive metallic sulfonamide-isatin ligands against promising drug targets”, J Mol Str, vol. 1277, 2023, DOI: https://doi.org/10.1016/j.molstruc.2022.134780.
D.E.V. Pires, T.L Blundell, and D.B. Ascher, “pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures” J. Med. Chem, vol. 58, pp. 4066-4072, 2015, DOI: https://doi.org/10.1021/acs.jmedchem.5b00104.
A. Daina, O. Michielin, and V. Zoete, “SwissADME : a free web tool to evaluate pharmacokinetics , drug- likeness and medicinal chemistry friendliness of small molecules” Nat Publ Group, pp. 1-13, 2017, DOI: https://doi.org/10.1038/srep42717.
C.B. Jalkute, and S.H. Barrage, “Identification of Angiotensin Converting Enzyme Inhibitor : An In Silico Perspective”, Int J Pept Res Ther, vol. 21, pp.107-115, 2015, DOI: https://doi.org/10.1007/s10989-014-9434-8.
D. Van Der Spoel, E. Lindahl, B. Hess, G. Groenhof, A.E. Mark, and H.J.C. Berendsen “GROMACS: fast, flexible, and free”, J Comput Chem, vol. 26, pp. 1701-1718, 2005, DOI: https://doi.org/10.1002/jcc.20291.
Dassault Systèmes BIOVIA Discovery Studio Modeling Environment, Release 2017, Dassault Systèmes, 2016.
A.M. Dar, and S. Mir, “Molecular Docking: Approaches, Types, Applications and Basic Challenges”, J Anal Bioanal Tech, vol. 8(2), pp. 1-7, 2017, DOI: https://doi.org/10.4172/2155-9872.1000356.
A. Belhassan, H. Zaki, A Aouidate, M. Benlyas, T. Lakhlifi, and M. Bouachrine, “Interactions between (4Z)-hex-4-en-1-ol and 2-methylbutyl 2-methylbutanoate with olfactory receptors using computational methods”, Moroc J Chem, vol. 7, pp. 7-1, 2019, DOI: https://doi.org/10.48317/IMIST.PRSM/morjchem-v7i1.12247.
C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney, “Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings”, Adv Drug Deliv Rev, vol 23(1-3), pp. 3-25, 1997, https://doi.org/10.1016/S0169-409X(96)00423-1.
A. Hospital, J.R. Goñi, M. Orozco and J.L.Gelpí, “Molecular dynamics simulations: advances and applications” Adv Appl Bioinform Chem, vol. 8, pp. 37-47, 2015, DOI: https://doi.org/10.2147%2FAABC.S70333.
B. Yabrir, A. Belhassan, T. Lakhlifi, G.M. Salgado, M. Bouachrine, P.C. Munoz, L.C. Gerli, and R.T. Ramirez, “Minor composition compounds of algerian herbal medicines as inhibitors of SARS-CoV-2 main protease: molecular docking and ADMET properties prediction”, J Chil Chem Soc, vol. 66(1), pp. 5067-5074, 2021, DOI: http://dx.doi.org/10.4067/S0717-97072021000105067.
A.G. Al-Sehemi, M. Pannipara, R.S. Parulekar, J.T. Kilbile, P.B. Choudhari, and M.H. Shaikh, “In silico exploration of binding potentials of anti SARS-CoV-1 phytochemicals against main protease of SARS-CoV-2”, J Saudi Chem Soc, 26, 101453, 2022, DOI: https://doi.org/10.1016/j.jscs.2022.101453.
S. Gowrishankar, S. Muthumanickam, A. Kamaladevi, C. Karthika, R. Jothi, P. Boomi, et al., “Promising phytochemicals of traditional Indian herbal steam inhalation therapy to combat COVID-19 - An in silico study”, Food Chem Toxicol, 148, 111966, 2021, DOI: https://doi.org/10.1016/j.fct.2020.111966.
T. Ongtanasup, S. Wanmasae, S. Srisang, C. Manaspon, S. Net-anong, and K. Eawsakul, “In silico investigation of ACE2 and the main protease of SARS-CoV-2 with phytochemicals from Myristica fragrans (Houtt.) for the discovery of a novel COVID-19 drug”, Saudi J Biol Sci, 29, 103389, 2022, DOI: https://doi.org/10.1016/j.sjbs.2022.103389.
H. Rajaram, N. Harshitha, S.A. Ram, S.M. Patra, V. Niranjan, and K.A. Vishnumurthy, “ Targeting non-structural proteins and 3CLpro in SARS-CoV-2 virus using phytochemicals from medicinal plants - In-silico approach”, J Ind Chem Soc, 99, 100488, 2022, DOI: https://doi.org/10.1016/j.jics.2022.100488.
S. Vardhan, and S.K. Sahoo, “In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19”, Comp Biol Med, 124, 103936, 2020, DOI: https://doi.org/10.1016/j.compbiomed.2020.103936.
M. Abdalla, R.K. Mohapatra, A.K. Sarangi, P.K. Mohapatra, W. Ali Eltayb, and M. Alam, “In silico studies on phytochemicals to combat the emerging COVID-19 infection”, J Saudi Chem Soc, 25, 101367, 2021, DOI: https://doi.org/10.1016/j.jscs.2021.101367.
P.K. Mohapatra, K.S. Chopdar, G.C. Dash, A.K. Mohanty, and M.K. Rava, “In silico screening and covalent binding of phytochemicals of Ocimum sanctum against SARS-CoV-2 (COVID 19) main protease”, J Biomol Struct Dyn, vol. 41(2), pp.435-444, 2023, DOI: https://doi.org/10.1080/07391102.2021.2007170.
S. Vincent, S. Arokiyaraj, M. Saravanan, and M. Dhanraj, “Molecular Docking Studies on the Anti-viral Effects of Compounds From Kabasura Kudineer on SARS-CoV-2 3CLpro”, Front Mol Biosci, vol. 7, 613401, 2020, DOI: https://doi.org/10.3389/fmolb.2020.613401.
T.T. Ai My, H.T.P. Loan, N.T.T. Hai, L.T. Hieu, T.T. Hoa, and B.T.P. Thuy, “Evaluation of the Inhibitory Activities of COVID-19 of Melaleuca cajuputi Oil Using Docking Simulation”, ChemistrySelect, vol.5, pp. 6312 -6320, 2020, DOI: https://doi.org/10.1002/slct.202000822.
L.N. AL-Eitan, A.Y. Almasri, and R.H. Khasawneh, “Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy”, Saudi Pharm J, vol. 27, pp. 484-490, 2019, DOI: https://doi.org/10.1016/j.jsps.2019.01.011.
Y.T. Chua, X.L. Ang, X.M. Zhong, and K.S. Khoo, “Interaction between warfarin and Chinese herbal medicines”, Singapore Med J, vol. 56(1), pp. 11-18, 2015, DOI: https://doi.org/10.11622%2Fsmedj.2015004.
A. Popov Aleksandrov, I. Mirkov, M. Ninkov, D. Mileusnic, J. Demenesku, V. Subota, et al., “Effects of warfarin on biological processes other than haemostasis: A review”, Food Chem Toxicol, vol. 113, pp. 19-32, 2018, DOI: https://doi.org/10.1016/j.fct.2018.01.019.
I. Piatkov, C. Rochester, T. Jones, and S. Boyages, “Warfarin Toxicity and Individual Variability—Clinical Case”, Toxins (Basel), vol. 2(11), pp. 2584-2592, 2010, DOI: https://doi.org/10.3390/toxins2112584.
M. Flemming, B. Kraus, A. Rascle, G. Jürgenliemk, S. Fuchs, R. Fürst, and J. Heilmann, “Revisited anti-inflammatory activity of matricine in vitro: Comparison with chamazulene”, Fitoterapia, vol. 106, pp. 122-128, 2015, DOI: https://doi.org/10.1016/j.fitote.2015.08.010.
J. Buckle. Basic Plant Taxonomy, Chemistry, Extraction, Biosynthesis, and Analysis, in Clinical aromatherapy. Essential Oils in Practice, 2nd Edition, 2003, pp. 38-75. DOI: https://doi.org/10.1016/B978-044307236-9.50009-6
R.A. Lobo. Menopause and Aging, in Yen and Jaffe's Reproductive Endocrinology (Eighth Edition), 2019, pp. 322-356. DOI: https://doi.org/10.1016/B978-0-323-47912-7.00014-7
Y.A. Heo, “Prasterone: A Review in Vulvovaginal Atrophy”, Drugs & Aging, vol. 36(8), pp. 781-788, 2019, DOI: https://doi.org/10.1007/s40266-019-00693-6.
H.S. Huang, X.H. Han, B.Y. Hwang, J.I. Park, S.K. Yoo, H.S. Choi, S.C. Lim and M.K. Lee, “Catalponol enhances dopamine biosynthesis and protects against l-DOPA-induced cytotoxicity in PC12 cells”, J Asian Nat Prod Res, vol. 11(10), pp. 867-875, 2009, DOI: https://doi.org/10.1080/10286020903193094.
A. Belhassan, S. Chtita, H. Zaki, T. Lakhlifi, and M. Bouachrine, “Molecular docking analysis of N-substituted oseltamivir derivatives with the SARS-Cov-2 main protease”, Bioinformation, vol. 16, pp. 404-408, 2020, DOI: https://doi.org/10.6026/97320630016404.
O. Chouitah, “Chemical Composition and Antimicrobial Activities of the Essential Oil from Glycyrrhiza glabra Leaves”, J Essent Oil-Bear Plants, vol. 14(3), pp. 284-288, 2011, DOI: https://doi.org/10.1080/0972060X.2011.10643935.
S. Soleiman-Meigooni, N.H. Yekta, H.R. Sheikhan, M. Aminianfar, R.Hamidi-Farahani, and M. Ahmadi, “Efficacy of a standardized herbal formulation from Glycyrrhiza glabra L. as an adjuvant treatment in hospitalized patients with COVID-19: A Randomized Controlled trial”, J Ayurveda Integr Med, vol. 13(4), 100670, 2022, DOI: https://doi.org/10.1016/j.jaim.2022.100670.
S.K. Sinha, S.K. Prasad, M.A. Islam, S.S. Gurav, B.B. Patil, N.A. AlFaris, et al., “Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: a pharmacoinformatics study”, J Biomol Struct Dyn, vol. 39 (13), pp. 4686-4700, 2021, DOI: https://doi.org/10.1080/07391102.2020.1779132.
S.K. Sinha, S.K. Prasad, M.A. Islam, S.K. Chaudhary, S. Singh, and A. Shakya, “Potential leads from liquorice against SARS-CoV-2 main protease using molecular docking simulation studies”, Comb Chem High Throughput Screen, vol. 24(4), pp. 591-597, 2021, DOI: https://doi.org/10.2174/1386207323999200817103148.
Cómo citar
IEEE
ACM
ACS
APA
ABNT
Chicago
Harvard
MLA
Turabian
Vancouver
Descargar cita
Licencia
Derechos de autor 2023 YABRIR YABRIR, Assia BELHASSAN, Guillermo Salgado MORAN , Tahar LAKHLIFI, Mohammed BOUACHRINE, Lorena Gerli CANDIA
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons (CC. Atribución 4.0) que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
